July 2026 in “Research Society and Development” This study reviewed recent advancements in treating androgenetic alopecia, reporting that while minoxidil and 5-alpha-reductase inhibitors remain well-supported treatments, emerging therapies like microneedling, platelet-rich plasma, low-level laser, and regenerative medicine show promising complementary results.
July 2026 in “Más dermatología” This study, published in "Más Dermatol," explores how multiple factors contribute to hair loss, such as genetics, hormones, oxidative stress, microinflammation, and emotional stress, and highlights interventions targeting these causes to improve hair regrowth and quality of life.
December 2024 in “Journal of General-Procedural Dermatology & Venereology Indonesia” In this study, a topical hair growth serum containing ingredients like procapil and redensyl was found to be safe and effective for subjects with androgenic alopecia, significantly improving hair density, thickness, and Anagen:Telogen ratio after 120 days, with no observed adverse effects.
In a randomized, double-blinded, placebo-controlled clinical trial, this study found that the botanical-based compound ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This preprint reports meaningful improvements in hair density and scalp coverage in an elderly female with androgenetic alopecia treated through an integrative regenerative protocol, involving microneedling and plant-derived exosomes, among other non-pharmacological interventions focusing on cellular senescence pathways.
